Reaffirmed: Knight Therapeutics (TSE:GUD) Buy Rating Maintained by GMP FirstEnergy; $10 Target in Place

Knight Therapeutics Inc. (TSE:GUD) Logo

Knight Therapeutics (TSE:GUD) Rating Reaffirmed

GMP FirstEnergy now has a $10 price target on shares of Knight Therapeutics (TSE:GUD). The price target would suggest a potential upside of 24.84 % from the last close price of Knight Therapeutics (TSE:GUD). This rating was released in analysts report on 15 March.

The stock increased 6.09% or $0.46 during the last trading session, reaching $8.01. About 3.54M shares traded or 1216.80% up from the average. Knight Therapeutics Inc. (TSE:GUD) has 0.00% since March 16, 2018 and is . It has underperformed by 4.37% the S&P500.

Knight Therapeutics Inc. operates as a specialty pharmaceutical firm in Canada and internationally. The company has market cap of $1.14 billion. The firm is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It has a 36.91 P/E ratio. The Company’s commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

More recent Knight Therapeutics Inc. (TSE:GUD) news were published by: Theglobeandmail.com which released: “Knight Therapeutics Inc (GUD-T) Quote – The Globe and Mail” on November 15, 2017. Also Seekingalpha.com published the news titled: “Knight Therapeutics: The Outsider CEO You’ve Never Heard Of – Seeking Alpha” on November 09, 2016. Theglobeandmail.com‘s news article titled: “The week’s most oversold and overbought stocks on the TSX – The Globe and Mail” with publication date: December 28, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.